发明名称 |
Erythropoetinfusionsprotein |
摘要 |
<p>The present invention relates to recombinant fusion proteins wherein erythropoietin (EPO) is linked via its C-terminus to an Fc fragment, and wherein said recombinant fusion proteins are further carbamoylated at the primary amines of the fusion protein. More specifically the invention relates to carbamoylated EPO-Fc fusion proteins, wherein at least one, preferably two or more, lysine amine residues and/or the N-terminal amino acid of said fusion protein are carbamoylated. The carbamoylated EPO-Fc fusion proteins of the present invention having a reduced hematopoietic activity whereas the tissue regenerative activity, i.e. the nerval cell regenerative activity remains unaltered or is even enhanced as compared to unmodified EPO-Fc fusion proteins. The invention further relates to a process for the manufacture of such fusion proteins and to pharmaceutical compositions containing them, as well as to the use of such fusion proteins and pharmaceutical compositions for medical therapy.</p> |
申请公布号 |
DE602007001273(D1) |
申请公布日期 |
2009.07.23 |
申请号 |
DE20076001273T |
申请日期 |
2007.02.22 |
申请人 |
POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH |
发明人 |
WEIK, ROBERT;HEMETSBERGER, THOMAS;REDL, HEINZ |
分类号 |
C12N15/62;A61K38/18;C07K14/505 |
主分类号 |
C12N15/62 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|